Here, we show that both genetic ablation and pharmacological inhibition of TLR4 were able to attenuate the main clinical markers of cachexia in mice bearing Lewis lung carcinoma (LLC). The gene discussed is TLR4; the disease is Carcinoma, Lewis Lung.